A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00349635

Enrollment

148

Registered

2006-07-07

Start date

2004-10-31

Completion date

Unknown

Last updated

2007-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Weight loss and diet.

Brief summary

To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.

Interventions

DRUGMetformin and Metformin + Fenofibrate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Both genders, BMI ≥ 30 kg/m² and \<40 kg/m².

Exclusion criteria

* Known abnormal thyroid hormone levels, or high thyroid stimulating hormone (TSH) level.

Design outcomes

Primary

Measure	Time frame
Weight	—

Secondary

Measure	Time frame
Waist and hip circumference	—

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026